De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.

TitleDe novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.
Publication TypeJournal Article
Year of Publication2013
AuthorsXi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Zhu JJ, Wang SY, Qiu DK
JournalJournal of digestive diseases// J Dig Dis
Pagination439 - 45
Date Published2013//
ISBN Number1751-2980
Other Numbers101302699
Keywords*Hepatitis B Core Antigens/bl [Blood], *Hepatitis B/tm [Transmission], *Liver Transplantation/ae [Adverse Effects], *Living Donors, Antiviral Agents/tu [Therapeutic Use], Child, Preschool, Female, Hepatitis B Vaccines, Hepatitis B virus/ip [Isolation & Purification], Hepatitis B/pc [Prevention & Control], Hepatitis B/vi [Virology], Humans, Infant, Male, Retrospective Studies, Risk Factors

OBJECTIVE: The aim of this study was to analyze the incidence and risk factors of de novo hepatitis B virus (HBV) infection from hepatitis B core antibody (anti-HBc)-positive donors in pediatric living donor liver transplantation (LDLT)., METHODS: We retrospectively analyzed 46 recipients without pre-liver transplantation (LT) HBV infection evidence who underwent LDLT from October 2006 to May 2011 in our center. HBV markers, including hepatitis B surface antigen (HBsAg) and antibody (anti-HBs), anti-HBc, hepatitis B e antigen (HBeAg) and antibody (anti-HBe) were determined in both donors and recipients before LT and in recipients after LT. HBV DNA titer was measured if the recipients were strongly suspected of de novo HBV infection., RESULTS: Without prophylaxis, de novo HBV infection occurred in 11 of 46 recipients (23.9%) 6-36 months after LT. All 11 patients received grafts from anti-HBc-positive donors. The donors' baseline status and the characteristics of recipients at the time of transplantation were not associated with the acquisition of de novo hepatitis B infection. The overall 2-year survival rate of patients from anti-HBc-positive donors was 84.2%. Two de novo HBV-infected patients who had YMDD mutation were given adefovir combined with lamivudine, and their liver function gradually improved during the follow-up period., CONCLUSIONS: Anti-HBc-positive donors can significantly increase the incidence of de novo HBV infection in HBsAg-negative recipients. Administration with adefovir in patients who are resistant to lamivudine seems to be an effective and safe way for de novo HBV infection.Copyright © 2013 Wiley Publishing Asia Pty Ltd and Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine.

Notify Library Reference ID4495

Related Incidents